For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Summary of Significant Accounting Policies - Sales by Product (Details)	12 Months Ended
	Mar. 02, 2019	Mar. 03, 2018	Mar. 04, 2017
Fiscal Year
Length of reporting period	364 days	364 days	371 days
Finite-Lived Intangible Asset, Useful Life	5 years
Prescription drugs \| Pharmacy sales \| Retail Pharmacy
Product Class
Percentage of sales	66.60%	65.90%	66.00%
Over-the-counter medications and personal care \| Pharmacy sales \| Retail Pharmacy
Product Class
Percentage of sales	10.80%
Health and beauty aids \| Pharmacy sales \| Retail Pharmacy
Product Class
Percentage of sales	5.00%
General merchandise and other \| Pharmacy sales \| Retail Pharmacy
Product Class
Percentage of sales	17.60%